Second primary malignancies in postpolycythemia vera and postessential thrombocythemia myelofibrosis: A study on 2233 patients Par MarcGuevreguian|2021-03-23T10:02:16+01:00février 27th, 2019| Lire la suite
Luspatercept for the treatment of anemia in myelodysplastic syndromes and primary myelofibrosis Par MarcGuevreguian|2021-03-23T10:12:11+01:00février 21st, 2019| Lire la suite
Early objective response to avelumab treatment is associated with improved overall survival in patients with metastatic Merkel cell carcinoma Par MarcGuevreguian|2021-03-23T11:17:11+01:00février 5th, 2019| Lire la suite
Characteristics and outcomes of patients with essential thrombocythemia or polycythemia… Par MarcGuevreguian|2021-03-23T10:09:28+01:00janvier 24th, 2019| Lire la suite
Survival Outcomes in Patients With Previously Untreated BRAF Wild-Type Advanced Melanoma Treated With Nivolumab Therapy Par MarcGuevreguian|2021-03-23T11:21:32+01:00octobre 25th, 2018| Lire la suite
Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo Par MarcGuevreguian|2021-03-22T20:55:22+01:00octobre 4th, 2018| Lire la suite
Ropeginterferon alpha-2b targets JAK2V617F-positive polycythemia vera cells in vitro and in vivo Par MarcGuevreguian|2021-03-23T10:56:37+01:00octobre 4th, 2018| Lire la suite
Incidence, outcomes, and risk factors of pleural effusion… Par MarcGuevreguian|2021-03-23T10:59:48+01:00août 9th, 2018| Lire la suite
Ponatinib efficacy and safety in Philadelphia chromosome–positive leukemia Par MarcGuevreguian|2021-03-23T10:31:12+01:00juillet 26th, 2018| Lire la suite
Loss of the co-repressor GPS2 sensitizes macrophage activation… Par MarcGuevreguian|2021-03-23T10:49:10+01:00juillet 22nd, 2016| Lire la suite
